Alkermes plc
ALKSAlkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
Drugs in Pipeline
25
Phase 3 Programs
16
Upcoming Catalysts
2
Next Catalyst
May 2027
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
How ALKS's past catalysts played out
VIVITROL® 380 mg
Opiate Dependence
High Dose ALKS 5461
Major Depressive Disorder
ALKS 9072, Low Dose
Schizophrenia
VIVITROL 380 mg
Alcohol Dependence
ALKS 5461
Major Depressive Disorder
ALKS 9072
Schizophrenia
NTX/BUP
Opioid Use Disorder
ALKS 9072, Low
Schizophrenia
ALKS 2680, 4mg
Narcolepsy Type 1
ALKS 2680 Dose 2
Narcolepsy Type 1
ALKS 2680 Dose 1
Narcolepsy Type 1
ALKS 2680 Dose 3
Narcolepsy Type 2
Paliperidone Palmitate
Schizophrenia
ALKS 3831
Schizophrenia
ALK3831
Schizophrenia
OLZ/SAM
Schizophrenia
N1539
Hysterectomy
ALKS 2680
Narcolepsy Type 2
RDC-0313 (ALKS 33)
Binge Eating Disorder
Samidorphan (Low Dose)
Schizophrenia
Motrin
Dental Pain
ALKS33 (RDC-0313) (1 mg)
Alcohol Dependence
ALKS 37
Opioid-induced Constipation
TrIP-2D
Chronic Obstructive Pulmonary Disease (COPD)
RDC-1036 (ALKS 37)
Opioid-induced Constipation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VIVITROL® 380 mg | Phase 3 | Opiate Dependence | - | - |
High Dose ALKS 5461 | Phase 3 | Major Depressive Disorder | - | - |
ALKS 9072, Low Dose | Phase 3 | Schizophrenia | - | - |
VIVITROL 380 mg | Phase 3 | Alcohol Dependence | - | - |
ALKS 5461 | Phase 3 | Major Depressive Disorder | - | - |
ALKS 9072 | Phase 3 | Schizophrenia | - | - |
NTX/BUP | Phase 3 | Opioid Use Disorder | - | - |
ALKS 9072, Low | Phase 3 | Schizophrenia | - | - |
ALKS 2680, 4mg | Phase 3 | Narcolepsy Type 1 | - | - |
ALKS 2680 Dose 2 | Phase 3 | Narcolepsy Type 1 | - | - |
ALKS 2680 Dose 1 | Phase 3 | Narcolepsy Type 1 | - | - |
ALKS 2680 Dose 3 | Phase 3 | Narcolepsy Type 2 | - | - |
Paliperidone Palmitate | Phase 3 | Schizophrenia | - | - |
ALKS 3831 | Phase 3 | Schizophrenia | - | - |
ALK3831 | Phase 3 | Schizophrenia | - | - |
OLZ/SAM | Phase 3 | Schizophrenia | - | - |
N1539 | Phase 2 | Hysterectomy | - | - |
ALKS 2680 | Phase 2 | Narcolepsy Type 2 | - | - |
RDC-0313 (ALKS 33) | Phase 2 | Binge Eating Disorder | - | - |
Samidorphan (Low Dose) | Phase 2 | Schizophrenia | - | - |
Motrin | Phase 2 | Dental Pain | - | - |
ALKS33 (RDC-0313) (1 mg) | Phase 2 | Alcohol Dependence | - | - |
ALKS 37 | Phase 2 | Opioid-induced Constipation | - | - |
TrIP-2D | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
RDC-1036 (ALKS 37) | Phase 2 | Opioid-induced Constipation | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Alkermes plc's drug pipeline?→
CatalystAlert tracks 25 drug candidates in Alkermes plc's (ALKS) pipeline across Phase 3, Phase 2. Its lead program is VIVITROL® 380 mg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alkermes plc's next FDA catalyst?→
Alkermes plc's (ALKS) next tracked catalyst is a Phase 3 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALKS biotech catalysts?→
Add ALKS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alkermes plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.